GENE ONLINE|News &
Opinion
Blog

2021-06-02| In-DepthInterviews

The Maturation of Blood-Based Diagnostics to Nip Cancers in the Bud: An Interview with Dr. Jimmy Lin

by Rajaneesh K. Gopinath
Share To
The war against cancer is far from over, but modern medicine has made significant progress in winning some critical battles. Thanks to the rise of new modalities, cancer diagnosis and treatment have seen practice-changing advances. Liquid biopsy, the latest entrant to precision oncology, enables the screening of cancer prevalence and detects multiple cancers with a single blood test. However, there is merit in choosing to tackle one cancer at a time using a multi-pronged approach, says Dr. Jimmy Lin, Chief Scientific Officer of Freenome.

It's free! Log in now to read

LATEST
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top